TGRX-326

DRUG3 trials

Sponsors

Shenzhen TargetRx, Inc.

Conditions

Non Small Cell Lung CancerNon-small Cell Lung Cancer

Phase 1

TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)

Active, not recruitingNCT05441956

Shenzhen TargetRx, Inc.Non-small Cell Lung Cancer

Start: 2021-04-23End: 2025-10-31Updated: 2025-05-18

Phase 2

TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)

Active, not recruitingNCT05955391

Shenzhen TargetRx, Inc.Non-small Cell Lung Cancer

Start: 2023-01-18End: 2025-12-31Updated: 2025-05-18

Phase 3

TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

Active, not recruitingNCT06082635

Shenzhen TargetRx, Inc.Non Small Cell Lung Cancer

Start: 2023-12-14End: 2028-11-30Updated: 2025-05-18

Related Papers

Efficacy and safety of deulorlatinib (TGRX-326) in patients with locally advanced or metastatic ALK+ non–small cell lung cancer: A multicenter, open-label, pivotal phase 2 trial.

Journal of Clinical Oncology2026-05-28

Safety, Efficacy, and Biomarker Analysis of Deulorlatinib (TGRX-326) in Anaplastic Lymphoma Kinase-Positive NSCLC: A Multicenter, Open-Label, Phase 1/1b Trial.

2024-11-154 citations

First-in-human, multicenter phase Ⅰ study of TGRX-326 in patients with advanced ALK-positive non-small cell lung cancer.

Journal of Clinical Oncology2023-06-01